Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Other)

Overall Status

Recruiting

CT.gov ID

NCT05634694

Collaborator

(none)

Enrollment

Location

Anticipated Duration (Months)

1.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a single-center, prospective, observational and exploratory clinical study. The object of this study is to evaluate the consistency and accuracy of patient-derived organoid model of cholangiocarcinoma to predict the clinical chemotherapeutic efficacy, as well as the possibility of guiding the adjuvant chemotherapy.

Condition or Disease	Intervention/Treatment	Phase
Cholangiocarcinoma	Other: No interventions.

Detailed Description

The chemotherapeutic efficacy is heterogeneous among cholangiocarcinoma patients after radical resection, and an accurate and relatively convenient model evaluating the chemotherapeutic efficacy is still lacking. This study aims to prospectively evaluate the consistency of drug sensitivity between patient-derived organoid model and the actual clinical chemotherapeutic efficacy in cholangiocarcinoma patients, assisting in guiding precision medicine and making therapeutic decisions.

Drug sensitivity tests include single drug and drug combination. The organoids that are successfully cultured will be kept in liquid nitrogen for a specific time.

Study Design

Study Type:

Observational

Anticipated Enrollment :

40 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Clinical Study on the Drug Sensitivity Consistency of Patient-Derived Organoid Model and Actual Therapeutic Efficacies in Cholangiocarcinoma Patients Receiving Adjuvant Chemotherapy After Radical Resection

Anticipated Study Start Date :

Nov 30, 2022

Anticipated Primary Completion Date :

Dec 1, 2023

Anticipated Study Completion Date :

Dec 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Sun Yat-Sen Memorial Hospital of Sun Yat-sen University The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the exploration cohort.	Other: No interventions. No interventions.

Arm

Intervention/Treatment

Sun Yat-Sen Memorial Hospital of Sun Yat-sen University

The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the exploration cohort.

Other: No interventions.

No interventions.

Outcome Measures

Primary Outcome Measures

Progression-free survival status of cholangiocarcinoma patients after radical resection [12 months]
The cholangiocarcinoma patients after radical resection are regularly followed-up for the progression-free survival status.
Drug sensitivity of patient-derived tumor organoids [2 months]
The drug sensitivity is tested on patient-derived tumor organoids, which is evaluated using Promega CellTiter-Glo 3D Cell Viability Assay to calculate the relative IC50, and is compared with the actual chemotherapeutic efficacy of cholangiocarcinoma patients.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

The patient must sign an informed consent form;
Age 18-75 years old, both male and female;
ECOG performance status score (PS score) 0-2;
Child-Pugh score A period;
Cholangiocarcinoma with negative margins confirmed by histopathology;
Have not received any systemic treatment within 6 months;
The functional indicators of important organs meet the following requirements (1)Neutrophils≥1.5109/L; platelets≥100109/L; hemoglobin≥9g/dl; serum albumin≥3g/dl; (2)Thyroid-stimulating hormone (TSH) ≤ 2 times the upper limit of normal, and T3 and T4 are in the normal range; (3)Bilirubin ≤ 1.5 times the upper limit of normal; ALT and AST ≤ 3 times the upper limit of normal; (4)Serum creatinine ≤ 1.5 times the upper limit of normal, and creatinine clearance ≥ 60ml/min (calculated by Cockcroft-Gault formula);
For women who are not breastfeeding or pregnant, use contraception during treatment or 12 months after the end of treatment.

Exclusion Criteria:

Unresectable cholangiocarcinoma patients or postoperative diagnosis of cholangiocarcinoma recurrence and metastasis;
Past or simultaneous suffering from other malignant tumors;
Have used gemcitabine-based chemotherapy or radiotherapy within 6 months;
Severe cardiopulmonary and renal dysfunction;
Hypertension that is difficult to control with drugs (systolic blood pressure (BP) ≥140 mmHg and/or diastolic blood pressure ≥90mmHg) (based on the average of ≥3 BP readings obtained by ≥2 measurements);
Abnormal coagulation function (PT>14s), have bleeding tendency or are receiving thrombolysis or anticoagulation therapy;
After antiviral treatment, HBV DNA>2000 copies/ml, HCV RNA>1000;
A history of esophageal and gastric varices, significant clinically significant bleeding symptoms or a clear tendency to appear within 3 months before enrollment;
Active infections requiring systemic treatment; patients with active tuberculosis infection within 1 year before enrollment; a history of active tuberculosis infection more than 1 year before enrollment, and no formal anti-tuberculosis treatment or tuberculosis Still in the active period;
Human immunodeficiency virus (HIV, HIV1/2 antibody) positive;
A history of psychotropic drug abuse, alcohol or drug abuse;
Known to have a history of severe allergies to any platinum drugs, or gemcitabine;
Other factors judged by the investigator may affect the safety of the subjects or the compliance of the trial. Such as serious diseases (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors.